International Multicentric Pooled Analysis of Colon Cancer Trials Investigators, IMPACT:Efficacy of adjuvant 5FU and folinic acid in colon cancer. Lancet, 345: 939–944, 1995.
2.
AndreT., BoniC., Mounedji-BoudiafL.: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. NEJM, 350: 2343–2351, 2004.
3.
SargentD.J., WieandS., BenedettiJ.: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 12915 pts on 15 randomized trials. Proc ASCO, abst 3502, 2004.
4.
SmithR., ColangeloL., WieandS.: The occurence of severe enteropathy among patients with stage II/III resected CRC treated with FL plus FLOX. Gastrointestinal Cancer Symposium, September 2003 update 2004, abst 195.
5.
SaltzL.B., NiedzewieckiD., HollisD.: Irinotecan plus fluorouracil/leucovorin (IFL) vs fluorouracil/leucovorin alone (FL) in stage III colon cancer (CALGB C89803). Proc ASCO, abst 3500, 2004.
6.
WolmarkN., WieandS., LemberskyB.: A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of the NSABP protocol C-06. Proc ASCO, abst 3508, 2004.
7.
CassidyJ., ScheithauerW., McKendrickG.: Capecitabine (X) vs bolus 5FU/LV as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proc ASCO, abst 3509, 2004.
8.
MamounasE., WieandS., WolmarkN.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B vs Dukes’ C colon cancer: results from NSABP C-01, C-02, C-03, C-04 trials. J Clin Oncol, 17: 1349–1355, 1999.
9.
International Multicentric Pooled Analysis of B2 Colon Cancer Trials (IMPACT 2) Investigators:Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol, 17: 1357–1363, 1999.
10.
GillS., LoprinziC.L., SargentD.J.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefit and by how much?J Clin Oncol, 22: 1797–1806, 2004.
11.
GrayR.G., BarnwellJ., HillsR.: QUASAR: a randomized study of adjuvant chemoterapy vs observation including 3238 colorectal cancer pts. Proc ASCO, abst 3501, 2004.
12.
GoldbergR.M., SargentD.J., MortonR.F.: N9741: FOLFOX or reduced dose of IFL in advanced colorectal cancer. Final efficacy data from intergroup study. Proc ASCO, abst 3621, 2004.
13.
TournigandC., AndrèT., AchilleE.: FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 22: 229–237, 2004.
14.
DeGramontA., CervantesA., AndrèT.: OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. Proc ASCO, abst 3525, 2004.
15.
Van CutsemE., TwelvesC., TaberneroJ.: XELOX: mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective 1st line option for patients with metastatic colorectal cancer. Proc ASCO, abst 1023, 2003.
16.
GrotheyA., JordanK., KellnerO.: Randomized phase II trial of capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer. Proc ASCO, abst 1022, 2003.
17.
HurwitzH., FehrenbacherL., NovotnyW.: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. NEJM, 350: 2335–2342, 2004.
18.
TaberneroJ.M., Van CutsemE., SastreJ.: An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Proc ASCO, abst 3512, 2004.
19.
NordlingerB., PeschaudF., MalafosseR.: Resection of liver metastases from colorectal cancer: how can we improve results?Colorectal Dis, 5: 515–517, 2003.
20.
Van RijnsoeverM.M., ElsalehH., McCaulK.: DNA methylation in stage III colorectal cancer is a novel independent predictor of survival benefit from adjuvant 5-fluorouracil treatment. Proc ASCO, abst 1027, 2003.
